Effects of ranolazine on astrocytes and neurons in primary culture by Aldasoro Celaya, Martín et al.
RESEARCH ARTICLE
Effects of Ranolazine on Astrocytes and
Neurons in Primary Culture
Martin Aldasoro, Sol Guerra-Ojeda, Diana Aguirre-Rueda, Ma Dolores Mauricio, Jose
Ma Vila, Patricia Marchio, Antonio Iradi, Constanza Aldasoro, Adrian Jorda,
Elena Obrador, Soraya L. Valles*
Department of Physiology, School of Medicine, University of Valencia, Spain
* lilian.valles@uv.es
Abstract
Ranolazine (Rn) is an antianginal agent used for the treatment of chronic angina pectoris
when angina is not adequately controlled by other drugs. Rn also acts in the central nervous
system and it has been proposed for the treatment of pain and epileptic disorders. Under
the hypothesis that ranolazine could act as a neuroprotective drug, we studied its effects on
astrocytes and neurons in primary culture. We incubated rat astrocytes and neurons in pri-
mary cultures for 24 hours with Rn (10−7, 10−6 and 10−5 M). Cell viability and proliferation
were measured using trypan blue exclusion assay, MTT conversion assay and LDH release
assay. Apoptosis was determined by Caspase 3 activity assay. The effects of Rn on pro-
inflammatory mediators IL-β and TNF-α was determined by ELISA technique, and protein
expression levels of Smac/Diablo, PPAR-γ, Mn-SOD and Cu/Zn-SOD by western blot tech-
nique. In cultured astrocytes, Rn significantly increased cell viability and proliferation at any
concentration tested, and decreased LDH leakage, Smac/Diablo expression and Caspase
3 activity indicating less cell death. Rn also increased anti-inflammatory PPAR-γ protein
expression and reduced pro-inflammatory proteins IL-1 β and TNFα levels. Furthermore,
antioxidant proteins Cu/Zn-SOD and Mn-SOD significantly increased after Rn addition in
cultured astrocytes. Conversely, Rn did not exert any effect on cultured neurons. In conclu-
sion, Rn could act as a neuroprotective drug in the central nervous system by promoting
astrocyte viability, preventing necrosis and apoptosis, inhibiting inflammatory phenomena
and inducing anti-inflammatory and antioxidant agents.
Introduction
Ranolazine (Rn), a piperazine derivative, is indicated for the treatment of refractory chronic
stable angina, in combination with other anti-ischemic drugs [1,2]. In contrast to other agents,
Rn does not significantly modify systemic blood pressure or heart rate [3,4]. Rn produces car-
diovascular benefits by inhibiting the late inward sodium current (late INa) [5]. Late INa ampli-
tude is increased in many pathological situations, such as myocardial ischemia and oxidative
stress [6,7]. At therapeutic concentrations, Rn inhibits ICa channels [8] and the slowly
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inactivating components of the sodium current (late INa), reducing tissue damage caused by
intracellular sodium and calcium overload associated with myocardial ischemia [9,10].
In addition to its antianginal effects, Rn acts as an anti-inflammatory agent by reducing
asymmetric dimethylarginine and C-reactive protein plasma levels, and by promoting endo-
thelial release of vasodilator mediators in patients with ischemic coronary disease [11]. Fur-
thermore, it has been described metabolic effects, such as the lowering of hemoglobin A1C
(HbA1c) in patients with ischemic heart disease and diabetes [12], or the improvement of insu-
lin secretion and β-cell survival in diabetic mice [13].
Moreover, several studies have evaluated the effects of Rn on central nervous system (CNS).
By decreasing neuronal excitability, Rn acts as an anticonvulsant agent [14,15], and has been
proposed as a possible treatment for neuropathic pain [16]. It has been suggested that these
effects would be mediated by late INa or inwardly rectifying K
+ current [17], enabling the devel-
opment of new treatment strategies for chronic pain [18], or epileptic disorders [19].
Among neural cells, astrocytes play different roles, such as structural support and mainte-
nance of the blood brain integrity [20], and are involved in immunological responses and
reparative processes that occur at different stages of neuroinflammation [21]. Astrocytes pro-
duce both neurotropic and inflammatory cytokines, and express receptors for mediators such
as IL-1β, TNF-α, among others [22,23]. We have recently determined, using mixed glial-neuro-
nal cultures, that astrocytes protect neurons from toxic agents, such as Aβ1–42, through mito-
chondrial biogenesis increase [24], and that some drugs can increase cell viability and anti-
inflammatory response in astrocytes, preventing cell death and inflammation induced by
Aβ1–42 [25].
Therefore, the purpose of this study is to investigate the effects of Rn on cell viability, apo-
ptosis, inflammation and oxidative stress in astrocytes and neurons in primary culture.
Material and Methods
Materials
The study was approved by the Bioethics Committee of the School of Medicine of the Univer-
sity of Valencia, Spain (number A1265026030697). All animals were handled according to
the recommendations of the Committee. Dulbecco’s modified Eagle’s medium (DMEM) and
foetal bovine serum (FBS) were obtained from Gibco (Gibco Invitrogen Corporation, Barce-
lona, Spain). Ranolazine (Rn) was obtained from Sigma-Aldrich biotechnology and dissolved
in Krebs solution to the proper final concentration (10−7, 10−6, 10−5 M). 3-(4,5-dimethyl-
2-thiazolyl)-2,5-dipheniyl-2H-tetrazolium bromide (MTT) was purchased from Sigma
Chemical Co. (St Louis, MO). Enzyme-linked immunosorbent assay (ELISA) kits for IL-1β
and TNF-α from Pierce Biotechnology, Inc. (Rockford, USA). Western Blot Chemilumines-
cent Detection System (ECL) was from Amersham (Amersham Biosciences, Barcelona,
Spain). Monoclonal anti-peroxisome proliferator-activated receptor antibody (PPAR-γ)
(1:250) from Sigma Aldrich (Madrid, Spain). Monoclonal anti-Smac/Diablo antibody (1:250)
from Santa Cruz Biotechnology (Madrid, Spain). Polyclonal anti-Cu/Zn superoxide dismut-
ase antibody (Cu/Zn-SOD) (1:250) from Assay Designs (Madrid, Spain). Monoclonal anti-
Mn superoxide dismutase (1:500) and anti-tubuline (1:1000) antibodies from Cell Signaling
(Beverly, MA, USA). Anti-GFAP (1:1000) and anti-MAP-2 (1:1000) antibodies from Sigma
Aldrich (Barcelona, Spain). Amyloid β1–42 was diluted to 100 μM in phosphate buffered
saline (PBS), and the oligomer preparations were aged for 24 h at 37°C, following manufac-
turer´s instruction (Sigma-Aldrich, Barcelona, Spain). All other reagents are analytical or cul-
ture grade purity.
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3-(4,5-dimethyl-2-thiazolyl)-2,5-dipheniyl-2H-
tetrazolium bromide.
Primary Culture of Cortical Astrocytes
Cerebral cortical astrocytes were isolated from rat foetuses of 21 days gestation. Foetuses were
obtained by cesarean section and decapitated. Cerebral cortices were removed and triturated
10–15 times through a Pasteur pipette. The cell suspension was filtered through nylon mesh
with a pore size of 90 μm and was diluted in DMEM containing 20% foetal bovine serum (FBS)
supplemented with L-glutamine (1%), HEPES (10 mM), fungizone (1%), and antibiotics (1%).
Cells were plated on T75 culture flask pretreated with poli-L-lysine. Cultures were maintained
in a humidified atmosphere of 5% CO2/95% air at 37°C during 20 days. After 1 week of culture,
the FBS content was reduced to 10%, and the medium was changed twice a week. By immuno-
cytochemistry, 97% of cells are GFAP positive (data not shown).
Primary Culture of Cortical Neurons
Primary cultures of rat cortical neurons were prepared from the cerebral cortex of 14-day old
rat foetuses. Briefly, the cerebral cortex of foetuses obtained under sterile conditions were dis-
sected and dissociated mechanically, by pipetting 10 times with 10 ml of DMEM (Gibco Invi-
trogen Corporation, Barcelona, Spain). The cell suspension was filtered through nylon mesh
with a pore size of 90 μm. Cell suspension was plated (5 x 104 cells/cm2) on poly- Lysine-
coated dishes. After attachment of the cells, the plating medium was changed to DMEM con-
taining 10% FBS supplemented with antibiotics (1%) and fungizone (1%). Cultures were grown
in a humidified atmosphere of 5% CO2/95% air at 37°C for 3 days. Cells were then exposed to
10 μM cytosine β-D arabino-furanoside on the third day of culture for 24 h to inhibit prolifera-
tion of non-neuronal cells. The medium was changed twice a week. By immunocytochemistry,
98% of cells are neurons (MAP-2 positive) (data not shown).
Trypan Blue Assay
Trypan blue exclusion assay was used to count the living cells and monitor cell proliferation.
Astrocytes were isolated and seeded at 7x104 cells/35 mm dish. After 5 days of culture, cells
were incubated without (control, C) or with Rn (10−7, 10−6, 10−5 M) for 24 h. 1.5% trypan blue
solution was applied to astrocytes cultures at room temperature for 3 min.
MTT Assay
Cell viability of the cultures was determined by the MTT assay. Cells were plated in 96 well cul-
ture plate and incubated with Rn during 24 h at different concentrations (10−7, 10−6 and 10−5
M). After cell treatments, the medium was removed and the cortical cells were incubated with
red free medium and MTT solution [0.5 mg/ml, prepared in phosphate buffer saline (PBS)
solution] for 4 h at 37°C. Finally the medium was removed and formazan particles were dis-
solved in dimethyl sulfoxide (DMSO). Cell viability, defined as the relative amount of MTT
reduction, was determined by spectrophotometry at 570 nm.
Lactate Dehydrogenase (LDH) Assay
To evaluate plasma membrane integrity, LDH release was determined by monitoring the leak-
age of the cytosolic LDH to the extracellular medium). LDH was measured spectrophotometri-
cally at 340 nm, following the rate of conversion of reduced nicotinamide adenine dinucleotide
to oxidized nicotinamide adenine dinucleotide.
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Caspase 3 Activity Assay
Caspase 3 activity was measured in cytosolic fractions by using a highly sensitive colorimetric
substrate, N-acetyl-Asp-Glu-Val-Asp p-nitroanilide (Ac-DEVD-pNA) following manufacturer
´s instructions (CalBiochem, La Jolla, CA). Enzyme activity was calculated using manufacturer
´s formulae, as pmol/min.
Cytokine Determination, IL-1 and TNFα
Cells were seeded, and at time of assay, the red phenol medium was removed and replaced by
PBS containing 1 mg/ml bovine serum albumin (BSA), either in the presence or absence of Rn
at different concentrations (10−7, 10−6 and 10−5 M). IL-1β and TNF-α concentration (pg/ml)
were ascertained using ELISA kits (Pierce Biotechnology, Inc.).
Western Blot Analysis
Cultured cells were treated with lysis buffer and then mechanically degraded to release the pro-
teins. Protein concentration was determined using modified Lowry method [26]. Loading
buffer (0.125 M Tris-HCl, pH 6.8, 2% SDS, 0.5% (v/v) 2-mercaptoethanol, 1% bromophenol-
blue and 19% glycerol) was added to protein sample and heated for 5 min at 95°C. Proteins
(20 μg) were separated on SDS-PAGE gels and transferred to nitrocellulose membranes in a
humid environment using a transfer buffer (25 mM Tris, 190 mM glycine, 20% methanol).
Membranes were blocked with 5% milk in TBS-T (0.05% Tween-20) and incubated with pri-
mary antibodies overnight at 4°C. Membranes were washed 3 times with wash buffer TBS-T
(TBS, 0.2% Tween-20) and incubated with a secondary anti-rabbit IgG or anti-mouse IgG (Cell
Signalling Technologies Danvers, MA) antibody conjugated to the enzyme horseradish peroxi-
dase (HRP) for 1 h. Membranes were washed three times and proteins were detected using the
ECL method as specified by the manufacturer. Autoradiography signals were assessed using
digital image system ImageQuant LAS 4000 (GE Healthcare). Densitometry is the quantitative
measurement of optical density in a photographic paper or photographic film, due to exposure
to light. Concentration of protein was determined by densitometric analysis, expressed as arbi-
trary units or relative densitometric units, relative to tubulin.
Statistical Analyses
Values are expressed as mean ± S.D. Statistical analysis were performed in two steps. First, an
analysis of variance was performed. Second, the sets of data in which F was significant were
performed using t-test (Student´s t test). Differences between groups were assessed by one-way
analysis of variance (ANOVA) performed with the program GraphPad Prism. Statistical signif-
icance was accepted at p 0.05.
Results
Rn and Cell Viability
Trypan blue exclusion assay was used to count the living cells and monitor cell proliferation.
Astrocytes were isolated and seeded at 7x104 cells/35 mm dish. After 5 days of culture, cells
were incubated without (control, C) or with Rn (10−7, 10−6, 10−5 M) for 24 h. In control condi-
tions proliferation was 0.9%, and previous incubation with Rn increased proliferation by 15%
(10-7M), 37% (10-6M) and 39% (10-5M) respectively (Table 1).
The role of Rn on cell viability was also studied using MTT conversion assay. Fig 1A shows
that incubation with Rn at different concentrations (10−7, 10−6 and 10−5 M), induced a
Ranolazine in Brain Primary Culture
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significant increase in astrocytes viability at any concentration tested (21% (10-7M), 40% (10-
6M) and 43% (10-5M)) compared with control cells.
Aβ1–42 (15μM) significantly decreased cell viability compared to control astrocytes (38%).
Incubation with Rn (10-6M) and the toxic peptide prevented the decrease in cell viability
induced by Aβ1–42.
Neurons previously incubated with Rn (10−7, 10−6 and 10−5 M) for 24 h showed no differ-
ences in cell viability compared to control cells (Fig 1B). Incubation of astrocytes with Rn (10−6
and 10−5 M) for 24 h decreased LDH (15% with Rn 10-6M and 20% with Rn 10-5M) release to
the medium and prevented LDH leakage induced by Aβ1–42 (15μM), indicating that astrocytes
are protected in some way by Rn (Fig 2A). Toxic peptide increased LDH release in about 75%
and incubation with Rn (10-6M) lowered by 60% LDH levels, indicating a protective effect
against Aβ1–42.
Caspase 3 and Smac/Diablo Expression
Incubation with Rn (10−6 and 10−5 M) for 24 h decreased Caspase 3 activity to 25% (Rn 10-6M)
and to 40% (Rn 10-5M), compared to control cells whereas activity was increased by treatment
with Aβ1–42 (15 μM) (Fig 2B). In the culture medium Aβ1–42 increased caspase-3 activity
(105%), that was reversed by Rn in 85%, (Fig 2B), indicating reduction of apoptosis after Rn
addition to the culture.
Fig 3 shows Smac/Diablo expression in astrocytes and neurons in culture. In astrocytes, Rn
decreased Smac/Diablo expression (4.4-fold at 10−6 M and 7.6-fold at 10−5 M) (Fig 3A). On the
other hand, we did not find any difference in cultured neurons compared to control cells at all
concentrations used (10−7, 10−6 and 10−5 M) (Fig 3B).
Table 1. Astrocytes proliferation and counting living cells. Astrocytes were isolated and seeded at 7x104 cells/35 mm dish during 5 days. At this time,
cells were incubated without Rn (control, C) or with Rn (10–7, 10–6, 10–5 M) for 24 h. Trypan blue exclusion was used to count the living cells and monitor
cell proliferation. Data are mean ± SD of four independent experiments (four different rats).
Seeding cells (x104/35 mm dish) 5 days of culture Rn 24h (x104/35 mm dish) % Proliferation
Control 7 12.47 ± 0.21 12.58 ± 0.18 0.9
Rn 10-7M 7 12.25 ± 0.32 14.09 ± 0.26 * 15
Rn 10-6M 7 12.18 ± 0.45 16.69 ± 0.25 * 37
Rn 10-5M 7 12.31 ± 0.51 17.11 ± 0.31 * 39
*p < 0.05 vs. control.
doi:10.1371/journal.pone.0150619.t001
Fig 1. Cell viability was determined by MTT assay in cells treated for 24 h. Astrocytes were incubated
without Rn (control, C), with Rn (10−7, 10−6, 10−5 M), with Amyloid β1–42 (15 μM) or with Amyloid β1–42 (15 μM)
+ Rn (10−6 M) (panel A). Neurons were incubated without (control, C) or with Rn (10−7, 10−6, 10−5 M) (panel
B). Data are mean ± SD of four independent experiments (four different rats). *p < 0.05 vs. control.
doi:10.1371/journal.pone.0150619.g001
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Rn and IL-1β Pro-Inflammatory Cytokine
Cultured astrocytes and neurons were incubated with Rn (10−7, 10−6 and 10−5 M) and secretion
of IL-1β was detected by ELISA. Fig 4 shows that, in astrocytes, Rn decreased 3.65, 4.14 and
4.53-fold IL-1β release at 10−7, 10−6 and 10−5 M respectively, compared with control values (Fig
4A). However, Rn did not change IL-1β release in neurons at any concentration tested (Fig 4B).
Rn and TNF-α Pro-Inflammatory Mediator
TNF-α levels were detected by ELISA. Fig 5 shows the effects elicited by Rn (10−7, 10−6 and
10−5 M) on astrocytes and neurons in primary culture. In astrocytes, Rn decreased 2.87, 4.21
and 6.63-fold TNF-α release at 10−7, 10−6 and 10−5 M respectively, compared to control cells
(Fig 5A). On the contrary, Rn did not induce any change in cultured neurons (Fig 5B).
Rn and PPAR-γ Expression
PPARs family regulates negatively gene expression of pro-inflammatory proteins. (Fig 6A and
6B) shows PPAR-γ expression in astrocytes and neurons in culture. Rn increased astrocytes
PPAR-γ expression 2.72-fold at 10−6 M and 2.84-fold at 10−5 M compared to control cells (Fig
6A). When Rn was added to cultured neurons, no changes in PPAR-γ expression were detected
at any concentration analyzed compared to controls (Fig 6B).
Rn and Cu/Zn-SOD Expression
Fig 7 shows Cu/Zn-SOD expression in astrocytes and neurons in primary culture. In astrocytes,
Rn increased Cu/Zn-SOD expression 4.49-fold at 10−6 M and 4.74-fold at 10−5 M compared to
Fig 2. Lactate dehydrogenase and caspase 3 activity. Astrocytes were incubated without Rn (control, C),
with Rn (10−7, 10−6, 10−5 M), with Amyloid β1–42 (15 μM) or with Amyloid β1–42 (15 μM) + Rn (10
−6 M) for 24 h.
Panel A: Lactate dehydrogenase activity was measured in supernatants of astrocytes. Panel B: Caspase 3
activity were determined as indicated under Materials and Methods. Data are means ± standard deviation of
three independent experiments (three different rats). *p < 0.05 versus control cells. #p < 0.05 versus Aβ-
treated cells.
doi:10.1371/journal.pone.0150619.g002
Fig 3. Smac/Diablo protein expression. Astrocytes (panel A) or neurons (panel B) were incubated without
Rn (control, C) or with Rn (10−7, 10−6, 10−5 M) for 24 h and collected to determine Smac/Diablo protein
expression byWestern blot. A representative immunoblot is shown in the top panel. Data are mean ± SD of
four independent experiments (four different rats). *p < 0.05 vs. control.
doi:10.1371/journal.pone.0150619.g003
Ranolazine in Brain Primary Culture
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control cells (Fig 7A). We also analyzed Rn effects in neurons, and we did not detect differences
in Cu/Zn-SOD expression compared to control cells at any concentration tested (Fig 7B).
Rn and Mn-SOD Expression
Fig 8 shows Mn-SOD expression in astrocytes and neurons in primary culture. In astrocytes,
Rn (10−6, 10−5 M) increased Mn-SOD expression 4.12-fold and 4.20-fold respectively com-
pared to control cells (Fig 8A). We also analyzed Rn effects in neurons and we did not detect
differences in Mn-SOD compared to control cells at any concentration tested (Fig 8B).
Discussion
The main findings of this study are that Rn decreased pro-inflammatory mediators IL-1β and
TNF-α release, and increased anti-inflammatory PPAR-γ as well as the antioxidant enzymes
Cu/Zn-SOD and Mn-SOD expressions in primary culture of astrocytes. Furthermore, Rn
increased astrocytes viability and proliferation and reduced LDH release, caspase 3 activity and
apoptosis activity via Smac/Diablo protein. On the other hand, we did not observe any effect of
Rn on neurons in primary culture.
Astrocytes are specialized neural cells playing different roles in the CNS, such as structural
and metabolic support to the brain, synthesis of glutathione and its precursors, brain trophic
role [21,27], and neuron protection against oxidative stress and inflammation [24,28,29]. The
exact mechanisms by which astrocytes protect neurons remain to be determined.
Anti-inflammatory substances can act in some glial cells [30]. Rn can cross blood brain bar-
rier, reaching in brain about one-third of plasma levels [19]. Rn acts as an anti-inflammatory
agent by reducing asymmetric dimethylarginine and C-reactive protein plasma levels [11],
Fig 4. Cytokine IL-1β determination. Astrocytes (panel A) or neurons (panel B) were incubated without Rn
(control, C) or with Rn (10−7, 10−6, 10−5 M) and cell culture supernatants were harvested. IL-1β secretion
were determined by ELISA. Values are means ± SD of replicate experiments from four independent
experiments (four different rats). *p < 0.05 vs control.
doi:10.1371/journal.pone.0150619.g004
Fig 5. Cytokine TNF-α determination. Astrocytes (panel A) or neurons (panel B) were incubated without Rn
(control, C) or with Rn (10−7, 10−6, 10−5 M) and cell culture supernatants were harvested. TNF-α secretion
were determined by ELISA. Values are means ± SD of replicate experiments from four independent cell
experiments (four different rats). *p < 0.05 vs control.
doi:10.1371/journal.pone.0150619.g005
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significantly reducing infarct size [31]. At therapeutic concentrations, Rn blocks voltage-gated
sodium channels (VGSCs), preferentially the late sodium current (INaL) [32]. Sodium channel
inhibitors exert neuro-protective effects in experimental models of brain ischemia [33] and
traumatic brain injury [34]. Moreover, phenytoin and carbamazepine were effective in animal
models of autoimmune encephalomyelitis (EAE) [35]. Additionally, tetrodotoxin attenuated
astrogliosis induced by an increase in voltage-gated sodium channels in an in vitro rat model of
mechanical injury [36].
Reactive astrogliosis occurs in response to CNS insults inducing changes in many astrocyte
functions, including oxidative stress and inflammation, contributing to CNS lesions [23]. Our
study demonstrates that Rn decreased pro-inflammatory cytokines TNF-α and IL-1β release in
cultured astrocytes. In normal conditions, there is a balance between pro- and anti-inflamma-
tory cytokines in order to maintain cell equilibrium. Most cytokines at very low concentrations
regulate cellular activities, including cell survival, growth, and differentiation [37]. Astrocytes
play a major role in neuro-inflammation and, depending on the stimulus, location and time
course of the insult, reactive astrocytes can exert both pro- and anti-inflammatory effects
[23,37]. Reactive astrogliosis [38] can be triggered by various inflammatory mediators such as
TNF-α and IL-1β [23,39]. Prolonged or uncontrolled inflammation results detrimental, exacer-
bating neural damage by overexpression of pro-inflammatory factors that enhance inflamma-
tion through a positive feedback loop, inducing the production of more cytokines or reactive
oxygen species (ROS), among other deleterious effects [23,37,39,40,41]. Pro-inflammatory
cytokines may increase neuronal excitability by releasing glutamate from astrocytes by a Ca2+-
dependent mechanism, resulting in excitotoxic injury to neurons, and also induce apoptosis in
Fig 6. PPAR-γ protein expression. Astrocytes (panel A) or neurons (panel B) were incubated without Rn
(control, C) or with Rn (10−7, 10−6, 10−5 M) for 24 h and collected to determine PPAR-γ protein expression by
Western blot. A representative immunoblot is shown in the top panel. Data are mean ± SD of four
independent experiments (four different rats). *p < 0.05 vs. control.
doi:10.1371/journal.pone.0150619.g006
Fig 7. Cu/Zn-SOD protein expression. Astrocytes (panel A) or neurons (panel B) were incubated without
Rn (control, C) or with Rn (10−7, 10−6, 10−5 M) for 24 h and collected to determine Cu/Zn-SOD protein
expression byWestern blot. A representative immunoblot is shown in the top panel. Data are mean ± SD of
four independent experiments (four different rats). *p < 0.05 vs. control.
doi:10.1371/journal.pone.0150619.g007
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neurons and glial cells [42]. In this sense, TNF-αmay directly elicit apoptosis through receptor
TNF-R1 whereas apoptosis induced by IL-1 depends on other mediators such as IFN-γ or
TNF-α. Pro-inflammatory cytokines can also provoke an increased production of neurotoxic
factors such as ROS and nitric oxide (NO) [37]. Elevated concentrations of pro-inflammatory
cytokines, including IL-1β and TNF-α, were found in blood, CSF and other tissues in Alzhei-
mer and Parkinson diseases, amyotrophic lateral sclerosis and severe subarachnoid hemor-
rhage, evidencing the participation of inflammation in the pathogenesis and outcome of these
diseases [37,40,43]. TNF-α can also induce the expression of other cytokines, such as IL-1, and
both have the capacity to induce IL-6, a marker for systemic inflammatory responses [44].
Sodium channel blockade attenuates the release of pro-inflammatory cytokines IL-1β and
TNF-α from stimulated microglia [45–47]. Blockade of sodium channels with phenytoin
reduced the LPS-stimulated secretion of IL-1 and TNF-α without affecting anti-inflammatory
IL-10 levels in an experimental model of autoimmune encephalomyelitis (EAE), attenuating
the severity of the disease [47]. In our study Rn decreased pro-inflammatory cytokine release
in all range of concentrations assayed. Rn was tested at concentrations corresponding to those
with therapeutic effect [13].
We also demonstrated for the first time an increase in PPAR-γ expression in primary cul-
tured astrocytes treated with Rn. PPAR-γ is a ligand-activated transcription factor that affects
the expression or activity of several genes, including those involved in the regulation of glucose
homeostasis, energy metabolism and inflammation [48,49]. Evidence supports the role of
PPAR-γ as anti-inflammatory factor [49]. It has been demonstrated that PPAR-γ agonists act
as neuroprotective agents against neurodegenerative diseases, such as stroke [48], Alzheimer's
[48,50,51] and Parkinson´s disease [48]. Additionally, Hu et al, in a mouse skeletal model,
found that PPAR-γ improves cellular storage of energy and increases insulin signaling, with
beneficial effects on metabolic health and tissue repair [52]. Inflammation contributes to sec-
ondary brain damage and some studies have shown that PPAR-γ reduces inflammation after
ischemic and hemorrhagic stroke [53–55]. Furthermore, activation of PPAR-γ suppress NF-κB
[56,57], which controls the expression of various genes involved in inflammatory responses
[58]. Recent data suggest that NF-κB inhibitory pathway may stimulate N2 neutrophils pheno-
type with neuroprotective effects [59]. PPAR-γ also participates in the polarization of macro-
phages toward the M2 phenotype, which is associated with anti-inflammatory actions and
tissue repair [60]. PPAR-γ agonists possess antitumor effects in combination with chemother-
apy drugs or other targeted therapies and may represent a promising strategy in the treatment
of malignancies [61,62]. In addition to its anti-inflammatory effect, PPAR-γ is known to upre-
gulate Cu/Zn-SOD expression [63]. This is in line with our results where Rn significantly
Fig 8. Mn-SOD protein expression. Astrocytes (panel A) or neurons (panel B) were incubated without Rn
(control, C) or with Rn (10−7, 10−6, 10−5 M) for 24 h and collected to determine Mn-SOD protein expression by
Western blot. A representative immunoblot is shown in the top panel. Data are mean ± SD of four
independent experiments (four different rats). *p < 0.05 vs. control.
doi:10.1371/journal.pone.0150619.g008
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increased PPAR-γ and Cu/Zn-SOD expression. Zhao et al, in a model of neuron-specific
PPAR-γ knockout mice, found that deficiency in neuron PPAR-γ expression leads to an
increase in brain damage in response to ischemia and oxidative insult [31]. Therefore, PPAR-γ
agonists might be useful to eliminate oxidative stress induced by ischemic damage and injured
brain [31,64]. Antioxidant molecules, such as Cu/Zn-SOD and Mn-SOD possess the PPAR-γ
positions in their promoter regions and their expressions are directly regulated by PPAR-γ
[65,66]. Rn enhances glucose oxidation in different conditions, including ischemia, which in
turn decreases fatty acid oxidation, improving oxygen consumption and reducing lactate pro-
duction [67], thus attenuating ischemic mitochondrial damage [68,69]. In astrocytes and
microglia, ROS and reactive nitrogen species are expressed in neurodegenerative diseases [70–
72]. The main antioxidant defence mechanism under this pathophysiological conditions
involves the activity of antioxidant enzymes such as superoxide dismutase (SOD). SOD regu-
lates the concentration of superoxide radicals by catalysing the change of superoxide to hydro-
gen peroxide (H2O2) [73]. It is possible that Rn plays an important role in this mechanism
since it has been reported that attenuates H2O2 release and hypoxia induced by INaL [74,75].
Trypan blue exclusion assay results indicate that an increase in proliferation occurs after Rn
addition in a concentration-dependent manner. The mechanisms underlying proliferation and
survival of astrocytes might include the MAPK signaling pathway, cell cycle regulatory mole-
cules and microRNAs, acting independently or together to regulate astrogenesis [76]. Further-
more, factors such as ciliary neurotrophic factor (CNTF) is implicated in adult neurogenesis
[77]. Astrocytes produce CNTF and express CNTF receptor α, therefore this factor could be
involved in astrogenesis. It remains to be determined whether ranolazine increases astrocytes
proliferation by augmenting CNTF.
Our MTT data indicate that Rn significantly increased astrocytes viability compared to con-
trol cells, without effects on cultured neurons. MTT assay is a well-established, widely used and
easily reproducible method for the assessment of cell viability and cytotoxicity when cells are
exposed to different substances [78,79]. Moreover, Rn decreased 15% (10-6M) and 20% (10-
5M) LDH leakage in control astrocytes, suggesting less cell death [80,81]. In addition, Rn pro-
tected astrocytes from the harmful effects of Aβ1–42. Toxic peptide induced an significantly
increased in about 75% in LDH release and incubation with Rn lowered by 60% LDH levels,
indicating a protective effect against the toxic peptide. The beneficial effects of Rn on central
nervous system need further studies. The effects of Rn on cell viability are probably depending
on cellular type. In our experiments, cells react differently when exposed to Rn, stimulating
astrocytes viability without effects on neurons. On the other hand, Rn decreased Caspase-3
activity to 25% (Rn 10-6M) and to 40% (Rn 10-5M), suggesting that Rn inhibits apoptosis in
astrocytes in primary culture. Furthermore, Aβ1–42 increased caspase-3 activity (105%) that
was reversed by Rn in 85%, showing that Rn prevents apoptosis induced by Aβ1–42.
Sequential activation of caspases plays a main role in cell apoptosis. Caspase 3 has critical
and multiple effects leading to apoptosis, especially under specific death inducers [82]. Apopto-
sis process is associated with the release of Cytochrome c and Smac/Diablo proteins [83,84]
from mitochondria into the cytosol in response to cytotoxic drugs or DNA damage. In this
sense, Rn diminishes Cytochrome c release in guinea pig isolated hearts [6]. Smac/Diablo pro-
duces apoptosis neutralizing one or more members of the IAP family (apoptosis inhibitory
proteins) [85]. Our results demonstrate a decrease in Smac/Diablo protein expression after Rn
addition in astrocytes compared to control cells. Therefore, it is possible that the decrease in
cell death that we found with Rn would be associated with the inactivation of the mitochondrial
apoptosis pathway.
In conclusion, our results demonstrate for the first time that ranolazine induces an increase
in astrocytes viability and proliferation, decreases cell death by reducing LDH release, and
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apoptosis by reduction of Smac/Diablo protein expression and Caspase 3 activity, diminishes
pro-inflammatory mediators IL-1β and TNF-α, and increases anti-inflammatory PPAR-γ,
anti-oxidant Cu/Zn-SOD and Mn-SOD protein expression in astrocytes in primary culture
(Fig 9). However, none of these effects were found in neurons in primary culture. Further stud-
ies will be needed to address the role of ranolazine as a neuro-protective agent against a variety
of neurological disorders, such as neurodegenerative, vascular, inflammatory, or traumatic
diseases.
Author Contributions
Conceived and designed the experiments: SLV MA. Performed the experiments: SGO DAR
MDM PMAJ CA EO. Analyzed the data: AI JV SLV. Contributed reagents/materials/analysis
tools: AJ PM CA. Wrote the paper: SLV MA.
References
1. Siddiqui MA, KeamMJ. Ranolazine: a review of its use in chronic stable angina pectoris. Drugs. 2006;
66: 693–710. PMID: 16620147
2. Sossalla S, Maier LS. Role of ranolazine in angina, heart failure, arrhythmias, and diabetes. Pharmacol
Ther. 2012; 133: 311–323. doi: 10.1016/j.pharmthera.2011.11.003 PMID: 22133843
3. Chaitman BR, Pepine CJ, Parker JO. Effects of ranolazine with atenolol, amlodipine, or diltiazem on
exercise tolerance and angina frequency in patients with severe chronic angina: a randomized con-
trolled trial. JAMA. 2004; 291: 309–316. PMID: 14734593
4. Chaitman BR, Skettino SL, Parker JO. Antiischemic effects and long-term survival during ranolazine
monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004; 43: 1375–1382. PMID:
15093870
5. Shryock JC, Belardinelli L. Inhibition of late sodium current to reduce electrical and mechanical dys-
function of ischaemic myocardium. Br J Pharmacol. 2008; 153: 1128–1132. PMID: 18071302
6. Aldakkak M, Camara AK, Heisner JS, Yang M, Stowe DF. Ranolazine reduces Ca2+ overload and oxi-
dative stress and improves mitochondrial integrity to protect against ischemia reperfusion injury in iso-
lated hearts. Pharmacol Res. 2011; 64:381–92. doi: 10.1016/j.phrs.2011.06.018 PMID: 21741479
7. Sokolov S, Scheuer T, Catterall WA. Gating pore current in an inherited ion channelopathy. Nature.
2007; 446: 76–78. PMID: 17330043
8. SchramG, Zhang L, Derakhchan K, Ehrlich JR, Belardinelli L, Nattel S. Ranolazine: ion-channel-block-
ing actions and in vivo electrophysiological effects. Br J Pharmacol. 2004; 142: 1300–1308. PMID:
15277312
9. Chaitman BR. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular
conditions. Circulation. 2006; 113: 2462–2472. PMID: 16717165
Fig 9. Rn effects in astrocytes in primary culture.Rn increases cell viability, anti-inflammatory response
and anti-oxidant proteins. On the other hand, Rn decreases pro-inflammatory mediators and necrosis-
apoptosis.
doi:10.1371/journal.pone.0150619.g009
Ranolazine in Brain Primary Culture
PLOS ONE | DOI:10.1371/journal.pone.0150619 March 7, 2016 11 / 15
10. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective
principle: effects of the late sodium current inhibitor ranolazine. Heart. 2006; IV(92): 6–14.
11. Deshmukh SH, Patel SR, Pinassi E, Mindrescu C, Hermance EV, Infantino MN, et al. Ranolazine
improves endothelial function in patients with stable coronary artery disease. Coron Artery Dis. 2009;
20: 343–347.
12. Morrow DA, Scirica BM, Chaitman BR, McGuire DK, Murphy SA, Karwatowska-Prokopczuk E et al.
MERLIN-TIMI 36 Investigators. Evaluation of the glycometabolic effects of ranolazine in patients with
and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation. 2009;
119: 2032–2039.
13. Ning Y, ZhenW, Jiang J, Liu D, Belardinelli L, Dhalla AK. Ranolazine increases β-cell survival and
improves glucose homeostasis in low-dose streptozotocin-induced diabetes in mice. J Pharmacol Exp
Ther. 2011; 337: 50–58. doi: 10.1124/jpet.110.176396 PMID: 21228065
14. Peters CH, Sokolov S, Rajamani S, Ruben PC. Effects of the antianginal drug, ranolazine, on the brain
sodium channel Na(V)1.2 and its modulation by extracellular protons. Br J Pharmacol. 2013; 169: 704–
716. doi: 10.1111/bph.12150 PMID: 23472826
15. Park YY, Johnston D, Gray R. Slowly inactivating component of Na+ current in peri-somatic region of
hippocampal CA1 pyramidal neurons. J Neurophysiol. 2013; 109: 1378–1390. doi: 10.1152/jn.00435.
2012 PMID: 23236005
16. Gould HJ 3rd, Garrett C, Donahue RR, Paul D, Diamond I, Taylor BK. Ranolazine attenuates behav-
ioral signs of neuropathic pain. Behav Pharmacol. 2009; 20(8):755–8. doi: 10.1097/FBP.
0b013e3283323c90 PMID: 19773645
17. Chen BS, Lo YC, Peng H, Hsu TI, Wu SN. Effects of ranolazine, a novel anti-anginal drug, on ion cur-
rents and membrane potential in pituitary tumor GH(3) cells and NG108-15 neuronal cells. J Pharmacol
Sci. 2009; 110: 295–305. PMID: 19609066
18. Cummins TR, Sheets PL, Waxman SG. The roles of sodium channels in nociception: Implications for
mechanisms of pain. Pain. 2007; 131: 243–257. PMID: 17766042
19. Kahlig K, Lepist I, Leung K, Rajamani S, George A. Ranolazine selectively blocks persistent current
evoked by epilepsy-associated Nav1.1mutations. Br J Pharmacol. 2010; 161: 1414–1426. doi: 10.
1111/j.1476-5381.2010.00976.x PMID: 20735403
20. Karve IP, Taylor JM, Crack PJ. (2015). The contribution of astrocytes and microglia to traumatic brain
injury. Br J Pharmacol. 2016; 173(4): 692–702. doi: 10.1111/bph.13125 PMID: 25752446
21. Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central
nervous system. Nat Rev Immunol. 2012; 12: 623–635. doi: 10.1038/nri3265 PMID: 22903150
22. Valles S, Borrás C, Gambini J, Furriol J, Ortega A, Sastre J, et al. Oestradiol or genistein rescues neu-
rons from amyloid beta-induced cell. Aging Cell. 2008; 7: 112–118. PMID: 18031570
23. Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010; 119: 7–35. doi:
10.1007/s00401-009-0619-8 PMID: 20012068
24. Aguirre-Rueda D, Guerra-Ojeda S, Aldasoro M, Iradi A, Obrador E, Ortega A, Mauricio MD, Vila JM,
Valles SL. Astrocytes protect neurons from Aβ1–42 peptide-induced neurotoxicity increasing TFAM
and PGC-1 and decreasing PPAR-γ and SIRT-1. Int J Med Sci. 2015; 12:48–56. doi: 10.7150/ijms.
10035 PMID: 25552918
25. Aguirre-Rueda D, Guerra-Ojeda S, Aldasoro M, Iradi A, Obrador E, Mauricio MD, Vila JM, Marchio P,
Valles SL. WIN 55,212–2, Agonist of Cannabinoid Receptors, Prevents Amyloid β1–42 Effects on
Astrocytes in Primary Culture. PLoS One. 2015; 10(4): e0122843. doi: 10.1371/journal.pone.0122843
PMID: 25874692
26. Peterson GL. A simplification of the protein assay method of Lowry et al. which is more generally appli-
cable. Anal.Biochem. 1977; 83: 346–356. PMID: 603028
27. Barreto GE, Gonzalez J, Torres Y, et al. Astrocytic-neuronal crosstalk: implications for neuroprotection
from brain injury. Neurosci Res. 2011; 71: 107–113. doi: 10.1016/j.neures.2011.06.004 PMID:
21693140
28. Skaper SD. The brain as a target for inflammatory processes and neuroprotective strategies. Ann. N.Y.
Acad. Sci. 2007; 122: 23–34.
29. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?
Nat. Medi. 2006; 12: 1005–1015.
30. Forshammar J, Jörneberg P, Björklund U, Westerlund A, Lundborg C, Biber B, et al. Anti-inflammatory
substances can influence some glial cell types but not others. Brain Res. 2013; 1539: 34–40. doi: 10.
1016/j.brainres.2013.09.052 PMID: 24120988
Ranolazine in Brain Primary Culture
PLOS ONE | DOI:10.1371/journal.pone.0150619 March 7, 2016 12 / 15
31. Zacharowski K, Blackburn B, Thiemermann C. Ranolazine, a partial fatty acid oxidation inhibitor,
reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 2001; 418:
105–110. PMID: 11334871
32. Zaza A, Belardinelli L, Shryock JC. Pathophysiology and pharmacology of the cardiac "late sodium cur-
rent". Pharmacol Ther. 2008; 119: 326–339. doi: 10.1016/j.pharmthera.2008.06.001 PMID: 18662720
33. Lei B, Cottrell JE, Kass IS. Neuroprotective effect of low-dose lidocaine in a rat model of transient focal
cerebral ischemia. Anesthesiology. 2001; 95: 445–451. PMID: 11506119
34. Huang XJ, Li WP, Lin Y, Feng JF, Jia F, Mao Q, et al. Blockage of the upregulation of voltage-gated
sodium channel nav1.3 improves outcomes after experimental traumatic brain injury. J Neurotrauma.
2014; 31: 346–357. doi: 10.1089/neu.2013.2899 PMID: 24313291
35. Black JA, Liu S, Carrithers M, Carrithers LM, Waxman SG. Exacerbation of experimental autoimmune
encephalomyelitis after withdrawal of phenytoin and carbamazepine. Ann Neurol. 2007; 62: 21–33.
PMID: 17654737
36. Pappalardo LW, Samad OA, Black JA, Waxman SG. Voltage-gated sodium channel Nav1.5 contrib-
utes to astrogliosis in an in vitro model of glial injury via reverse Na(+) /Ca(2+) exchange. Glia. 2014;
62:1162–1175. doi: 10.1002/glia.22671 PMID: 24740847
37. Smith JA, Das A, Ray SK, Banik NL. Role of pro-inflammatory cytokines released frommicroglia in
neurodegenerative diseases. Brain Res Bull. 2012; 87:10–20. doi: 10.1016/j.brainresbull.2011.10.004
PMID: 22024597
38. Block L, Jörneberg P, Björklund U, Westerlund A, Biber B, Hansson E. Ultralow concentrations of bupi-
vacaine exert anti-inflammatory effects on inflammation-reactive astrocytes. Eur J Neurosci. 2013; 38:
3669–3678. doi: 10.1111/ejn.12364 PMID: 24083665
39. Rossi D, Volterra A. Astrocytic dysfunction: insights on the role in neurodegeneration. Brain Res Bull.
2009; 80: 224–232. doi: 10.1016/j.brainresbull.2009.07.012 PMID: 19631259
40. Fuller S, Steele M, Münch G. Activated astroglia during chronic inflammation in Alzheimer's disease—
do they neglect their neurosupportive roles? Mutat Res. 2010; 690: 40–49. doi: 10.1016/j.mrfmmm.
2009.08.016 PMID: 19748514
41. Whitney NP, Eidem TM, Peng H, Huang Y, Zheng JC. Inflammation mediates varying effects in neuro-
genesis: relevance to the pathogenesis of brain injury and neurodegenerative disorders. J Neurochem.
2009; 108:1343–1359. doi: 10.1111/j.1471-4159.2009.05886.x PMID: 19154336
42. Choi SS, Lee HJ, Lim I, Satoh J, Kim SU. Human astrocytes: secretome profiles of cytokines and che-
mokines. PLoS One. 2014; 9(4): e92325. doi: 10.1371/journal.pone.0092325 PMID: 24691121
43. Kooijman E, Nijboer CH, van Velthoven CT, Mol W, Dijkhuizen RM, Kesecioglu J et al. Long-term func-
tional consequences and ongoing cerebral inflammation after subarachnoid hemorrhage in the rat.
PLoS One.2014; Mar 6; 9(6):e90584. doi: 10.1371/journal.pone.0090584 PMID: 24603553
44. Clark IA, Alleva LM, Vissel B. The roles of TNF in brain dysfunction and disease. Pharmacol Ther.
2010; 128: 519–548. doi: 10.1016/j.pharmthera.2010.08.007 PMID: 20813131
45. Black JA, Waxman SG. Noncanonical roles of voltage-gated sodium channels. Neuron. 2013; 80:
280–91. doi: 10.1016/j.neuron.2013.09.012 PMID: 24139034
46. Jung GY, Lee JY, Rhim H, Oh TH, Yune TY. An increase in voltage-gated sodium channel current elic-
its microglial activation followed inflammatory responses in vitro and in vivo after spinal cord injury.
Glia. 2013; 61: 1807–1821. doi: 10.1002/glia.22559 PMID: 24038428
47. Black JA, Liu S, Waxman SG. Sodium channel activity modulates multiple functions in microglia. Glia.
2009; 57: 1072–1081. doi: 10.1002/glia.20830 PMID: 19115387
48. Chen Y, Wu J, Tsai H, Huang C, Chen J, Sun G, et al. Peroxisome proliferator-activated receptor
gamma (PPAR-γ) and neurodegenerative disorders. Mol Neurobiol. 2012; 46: 114–124. doi: 10.1007/
s12035-012-8259-8 PMID: 22434581
49. Heneka M, Landreth G, Hüll M. Drug insight: effects mediated by peroxisome proliferator activated
receptor-gamma in CNS disorders. Nat Clin Pract Neurol. 2007; 3: 496–504. PMID: 17805244
50. Valles S, Dolz-Gaiton P, Gambini J, Borras C, Lloret A, Pallardo F, et al. Estradiol or genistein prevent
Alzheimer's disease-associated inflammation correlating with an increase PPAR gamma expression in
cultured astrocytes. Brain Res. 2010; 2: 138–144.
51. Wang H, Zhao Y, Zhang S, Liu G, KangW, Tang H, et al. PPAR-γ agonist curcumin reduces the amy-
loid-β-stimulated inflammatory responses in primary astrocytes. J Alzheimers Dis. 2010; 20: 1189–
1199. doi: 10.3233/JAD-2010-091336 PMID: 20413894
52. Hu S, Yao J, Howe A, Menke B, Sivitz W, Spector A, et al. Peroxisome proliferator-activated receptor γ
decouples fatty acid uptake from lipid inhibition of insulin signaling in skeletal muscle. Mol Endocrinol.
2012; 26: 977–988. doi: 10.1210/me.2011-1253 PMID: 22474127
Ranolazine in Brain Primary Culture
PLOS ONE | DOI:10.1371/journal.pone.0150619 March 7, 2016 13 / 15
53. Aronowski J, Hall C. New horizons for primary intracerebral hemorrhage treatment: experience from
preclinical studies. Neurol Res. 2005; 27: 268–279. PMID: 15845210
54. Sundararajan S, Landreth GE. Antiinflammatory properties of PPAR gamma agonists following ische-
mia. Drug News Perspect. 2004; 17: 229–236. PMID: 15334171
55. Luo Y, Yin W, Signore A, Zhang F, Hong Z, Wang S, et al. Neuroprotection against focal ischemic brain
injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J Neurochem.
2006; 97: 435–448. PMID: 16539667
56. Genolet R, Wahli W, Michalik L. PPARs as drug targets to modulate inflammatory responses? Current
Drug Targets: Inflammation and Allergy. 2004; 3: 361–375. PMID: 15584886
57. Wan H, Yuan Y, Qian A, Sun Y, Qiao M. Pioglitazone, a PPARgamma ligand, suppresses NFkappB
activation through inhibition of IkappaB kinase activation in cerulein-treated AR42J cells. Biomed. Phar-
macother. 2007; 62: 466–472. doi: 10.1016/j.biopha.2007.10.012 PMID: 18490130
58. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell. 2002; 109: S81–S96. PMID:
11983155
59. Cuartero M, Ballesteros I, MA NF, Vivancos J, Hamilton J, et al. N2 neutrophils, novel players in brain
inflammation after stroke: modulation by the PPARγ agonist rosiglitazone. Stroke. 2013; 44: 3498–
3508. doi: 10.1161/STROKEAHA.113.002470 PMID: 24135932
60. Bouhlel M, Derudas B, Rigamonti E, Dièvart R, Brozek J, Haulon S, et al. PPARgamma activation
primes humanmonocytes into alternative M2macrophages with anti-inflammatory properties. Cell
Metab. 2007; 6: 137–143. PMID: 17681149
61. Hatton J, Yee L. Clinical Use of PPARgamma Ligands in Cancer. PPAR Res. 2008; doi: 10.1155/2008/
159415
62. Belfiore A, Genua M, Malaguarnera R. PPAR-γ agonists and their effects on IGF-I receptor signaling:
Implications for cancer. PPAR Res. 2009; doi: 10.1155/2009/830501
63. Yoo H, ChangM, Rho H. Induction of the rat Cu/Zn superoxidedismutase gene through the peroxisome
proliferator-responsive element by arachidonic acid. Gene. 1999; 234: 87–91. PMID: 10393242
64. Zhao X, Strong R, Zhang J, Sun G, Tsien J, Cui Z, et al. Neuronal PPAR gamma deficiency increases
susceptibility to brain damage after cerebral ischemia. J Neurosci. 2009; 13: 6186–6195.
65. Chan P. Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow
Metab. 2001; 21: 2–14. PMID: 11149664
66. Inoue I, Goto S, Matsunaga T, Nakajima T, et al. The ligands/activators for peroxisome proliferator-acti-
vated receptor alpha (PPARalpha) and PPARgamma increase Cu2+,Zn2+-superoxide dismutase and
decrease p22phox message expressions in primary endothelial cells. Metabolism. 2001; 50:3–11.
PMID: 11172467
67. Ding G, Fu M, Qin Q, Lewis W, Kim HW, Fukai T, et al. Cardiac peroxisome proliferator-activated recep-
tor gamma is essential in protecting cardiomyocytes from oxidative damage. Cardiovasc Res 2007;
76:269–279. PMID: 17678635
68. McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. Ranolazine stimulates glucose oxidation in nor-
moxic, ischemic, and reperfused ischemic rat hearts. Circulation. 1996; 93: 135–142. PMID: 8616920
69. Gadicherla A, Stowe D, AntholineW, Yang M, Camara A. Damage to mitochondrial complex I during
cardiac ischemia reperfusion injury is reduced indirectly by anti-anginal drug ranolazine. Biochim Bio-
phys Acta. 2012; 1817: 419–429. doi: 10.1016/j.bbabio.2011.11.021 PMID: 22178605
70. Liberatore G, Jackson-Lewis V, Vukosavic S, Mandiras VM, Mcauliffe W, Dawson V, et al. Inducible
nitric oxide synthase estimulates dopaminergic neurodegeneration in the MPTPmodel of Parkinson
disease. Nat Med. 1999; 5: 1403–1409. PMID: 10581083
71. Knott C, Stern G, Wilkin G. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1,and
cyclooxygenases-1 and -2. Mol Cell Neuroscience. 2000; 16: 724–739.
72. Norenberg M. Reactive astrocytosis. Michael Aschner and Harold K. Kimelberg, editors. Therole of glia
in neurotoxicity. 1996; 93–107.
73. Fridovich I. Superoxide radical and superoxide dismutases. Annu Rev Biochem. 1995; 64: 97–112.
PMID: 7574505
74. Song YSJ, Belardinelli L. A slowly inactivating sodium current contributes to spontaneous diastolic
depolarization of atrial myocytes. Am J Physiol Heart Circ Physiol. 2009; 297: 1254–1262.
75. Ma J, Song Y, Shryock J, Hu L, WangW, Yan X, et al. Ranolazine Attenuates Hypoxia- and Hydrogen
Peroxide-Induced Increases in Sodium Channel Late Openings in Ventricular Myocytes. J Cardiovasc
Pharmacol. 2014; 64: 60–68. doi: 10.1097/FJC.0000000000000090 PMID: 24705174
76. Chi X, Horace H L, Ping-Yee L. Effects of addictive drugs on adult neural stem/progenitor cells. Cell Mol
Lif Sci. 2016; 73:327–348.
Ranolazine in Brain Primary Culture
PLOS ONE | DOI:10.1371/journal.pone.0150619 March 7, 2016 14 / 15
77. Yang P, Arnold SA, Habas A, Hetman M, Hagg T. Ciliary neurotrophic factor mediates dopamine D2
receptor-induced CNS neurogenesis in adult mice. J Neurosci. 2008; 28:2231–41. doi: 10.1523/
JNEUROSCI.3574-07.2008 PMID: 18305256
78. Rönicke R, Klemm A, Meinhardt J, Schröder UH, Fändrich M, Reymann KG. Abeta mediated diminu-
tion of MTT reduction—an artefact of single cell culture? PLoSOne 2008; Sep 18; 3(9):e3236. doi: 10.
1371/journal.pone.0003236 PMID: 18800168
79. Xing D, Wang J, Ou S, Wang Y, Qiu B, Ding D, et al. Expression of neonatal Nav1.5 in human brain
astrocytoma and its effect on proliferation, invasion and apoptosis of astrocytoma cells. Oncol Rep.
2014; 31: 2692–2700. doi: 10.3892/or.2014.3143 PMID: 24756536
80. Zhang R, Huang Q, Zou L, Cao X, Huang H, Chu X. Beneficial effects of deferoxamine against astro-
cyte death induced by modified oxygen glucose deprivation. Brain Res. 2014; 1583:23–33. doi: 10.
1016/j.brainres.2014.08.016 PMID: 25152469
81. GuWW, Lu SQ, Ni Y, Liu ZH, Zhou XY, Zhu YM et al. 2-(3',5'-Dimethoxybenzylidene) cyclopentanone,
a novel synthetic small-molecule compound, provides neuroprotective effects against ischemic stroke.
Neuroscience.2016; 316: 26–40. doi: 10.1016/j.neuroscience.2015.11.052 PMID: 26656221
82. Porter AG, Jänicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999; 6: 99–104.
PMID: 10200555
83. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts:
requirement for dATP and cytochrome c. Cell. 1996; 86: 33–42.
84. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-depen-
dent caspase activation by eliminating IAP inhibition. Cell. 2000; 86: 147–157.
85. Colin A, EmmaMC, and Seamus JMm. Apoptosis-associated release of Smac/DIABLO frommitochon-
dria requires active caspases and is blocked by Bcl-2. EMBO J. 2001; 20: 6627–6636. PMID:
11726499
Ranolazine in Brain Primary Culture
PLOS ONE | DOI:10.1371/journal.pone.0150619 March 7, 2016 15 / 15
